Home Newsfeeds Wedbush Maintains Neutral on Super Micro Computer, Raises Price Target to $65

Wedbush Maintains Neutral on Super Micro Computer, Raises Price Target to $65

Wedbush analyst Matt Bryson maintains Super Micro Computer (NASDAQ:SMCI) with a Neutral and raises the price target from $55 to $65.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Wedbush analyst Matt Bryson maintains Super Micro Computer (NASDAQ:SMCI) with a Neutral and raises the price target from $55 to $65.

Galmed’s Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model

By Vandana Singh

July 7, 10:18 AM

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment…

GLMD

News

The NFT Gaming Company Announces The Addition Of 2 New Games For 2023

By Benzinga Newsdesk

October 17, 9:11 AM

The NFT Gaming Company, Inc. ("NFTG" or the "Company"), a company developing a digital gaming platform and community that will offer users the ability to create unique avatars playable in all of the games on the platform

NFTG

Oppenheimer Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $8.5

By Benzinga Newsdesk

September 7, 5:08 AM

Oppenheimer analyst Francois Brisebois initiates coverage on Aquestive Therapeutics (NASDAQ:AQST) with a Outperform rating and announces Price Target of $8.5.

AQST

Analyst Ratings

4 Analysts Have This to Say About LegalZoom.com

By Benzinga Insights

September 21, 9:56 AM

Over the past 3 months, 4 analysts have published their opinion on LegalZoom.com (NASDAQ:LZ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Wedbush Maintains Neutral on Super Micro Computer, Raises Price Target to $65

Related Posts

Galmed’s Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model

The NFT Gaming Company Announces The Addition Of 2 New Games For 2023

Oppenheimer Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $8.5

4 Analysts Have This to Say About LegalZoom.com